1 / 4

GEFTINAT 250MG | GEFTICIP 250MG-Blueberry pharmaceuticals

Geftinat 250mg|Gefticip 250mg is considered as first line therapy in non-small cell lung carcinoma in metastatic stage, tumor cell containing epidermal growth factor receptors like exon 19 deletion or exon 21 substitution mutations which is identified by FDA approved test.<br>#Geftinat250mg #Gefticip250mg #Gefitinib250mg #Iressa

Emilymia
Download Presentation

GEFTINAT 250MG | GEFTICIP 250MG-Blueberry pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gefitinib (Iressa) |Blueberry pharmaceuticals GEFTINAT 250MG | GEFTICIP 250MG DESCRIPTION : Geftinat 250mg|Gefticip 250mg tablets are categorized as kinase inhibitor, which exhibits anti-cancer activity by undergoing mechanism like protein kinase inhibition. Geftinat 250mg|Gefticip 250mg contains an active compound known as Gefitinib which is chemically known as anilinoquinazoline which contains anti-neoplastic effects. Geftinat 250mg|Gefticip 250mg is a FDA approved product, manufactured by Natco pharma. GEFTINAT |GEFTICIP INDICATION AND USAGE Geftinat 250mg|Gefticip 250mg is considered as first line therapy in non-small cell lung carcinoma in metastatic stage, tumor cell containing epidermal growth factor receptors like exon 19 deletion or exon 21 substitution mutations which is identified by FDA approved test. Gefitinib (Iressa)250MG

  2. GEFTINAT |GEFTICIP UNDERGOING ADME The mean bioavailability of Gefitinib is 60% The peak plasma concentration time of Gefitinib is reaches within 3 to 7 hours after drug intake Gefitinib is distributed throughout the body and causes steady state volume of distribution in 1400L The human plasma protein bound of Gefitinib is occurs as 90%. The metabolism of Gefitinib is occurs through hepatically, by using CYP3A4 In metabolism of Gefitinib includes three sections of biotransformation as: 1. Metabolism of N-propoxymorpholino group 2. Methoxy substituent on quinazoline demethylation occur 3. Halogenated phenyl group undergoes oxidative defluorination The major active metabolite of Gefitinib is O desmethyl Gefitinib which is formed by CYP2D6 metabolism. Gefitinib is cleared away with the help of liver, with half life elimination occurring within 48 hours. The steady state plasma concentration is accomplished within 10 days after daily single dose. The elimination of Gefitinib is occurs through feces with the range of 86% and renal elimination also occurred with less than 4%. GEFTINAT |GEFTICIP DOSAGE AND ADMINISTRATION The usual prescribed dosage of Geftinat 250mg|Gefticip 250mg tablets are 250mg should be given orally as a single dose by administering with or without food continuously. If patient feel difficult

  3. for swallow the tablets, must immerse the tablets with 4 to 8 ounces of water and mix it well for relatively 15 minutes. Take the solution immediately through naso-gastric tube. DOSAGE ADJUSTMENT Refuse the Geftinat 250mg|Gefticip 250mg tablets, if patients have any of the following conditions such as; Acute outbreak or aggravation of pulmonary symptoms like cough, fever, dyspnea In case of elevation of ALT & AST levels; Severe ocular disorders like keratitis High skin reactions Geftinat 250mg|Gefticip 250mg therapy should be discontinuing forever; in case of Gastrointestinal perforation Enduring ulcerative keratitis Serious liver damage Interstitial lung disease STRONG CYP3A4 INDUCERS In the absence of adverse effects, the dosage is increased to 500mg; continue the Geftinat 250mg|Gefticip 250mg therapy with 250mg after cessation of strong CYP3A4 inducers THE MAJOR ADVERSE EFFECT OF GEFTINAT |GEFTICIP TABLETS OCCURS AS Liver toxicity Gastrointestinal perforation, Severe diarrhea, Bullous &exfoliative skin disorders, Ocular disorders, Interstitial lung disease THE MOST COMMON SIDE EFFECTS ARE Headache, Diarrhea, Fatigue Respiratory failure occurs due to pneumonia & pulmonary embolism, Nausea, Vomiting, Skin reactions, Nail disorders, Stomatitis, Loss of appetite, Conjunctivitis, Blepharitis, Dry eye, Mucosal inflammation, tongue ulceration, eye irritation, eyelid Pruritus, edema, Elevation of AST, ALT, Proteinuria, Hemorrhagic cystitis, Cutaneous vasculitis

  4. STORAGE AND HANDLING The storage of Geftinat 250mg|Gefticip 250mg tablet container should be kept at 20°C to 25°C (68°F to 77°F). Protect the container from moisture, heat and light. OVER DOSAGE OF GEFTINAT |GEFTICIP There is no distinct therapy for over dosage of Gefitinib, if over dosage occurs provide supportive care and monitor the patients frequently for the signs and symptoms of over dosage of Gefitinib. CONTACTS Phone : +91- 97890 77748 Email: info@blueberrypharma.com WEBSITE: https://blueberrypharma.com/gefitinib.php

More Related